{
    "nct_id": "NCT05002270",
    "official_title": "A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-21822 Monotherapy and Combination Therapy in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation",
    "inclusion_criteria": "* Participants must be able to provide an archived tumor sample\n* Histologically or cytologically confirmed solid tumors with KRAS G12C mutation\n* Must have received at least 1 prior standard therapy\n* Must have at least 1 measurable lesion per RECIST v1.1\n* Must have adequate organ function\n* Must be able to swallow and retain orally administered medication\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has brain or spinal metastases, except if treated and no evidence of radiographic progression or hemorrhage for at least 28 days\n* Active infection requiring systemic treatment within 7 days\n* Active HBV or HCV\n* Any severe and/or uncontrolled medical conditions\n* LVEF â‰¤50% assessed by ECHO or QTcF\n* QT interval >470 msec\n* Experiencing unresolved CTCAE 5.0 Grade >1 toxicities",
    "miscellaneous_criteria": ""
}